198 related articles for article (PubMed ID: 10951132)
1. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
Jury CS; McAllister EJ; MacKie RM
Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
[TBL] [Abstract][Full Text] [Related]
2. Serum S100--a marker for disease monitoring in metastatic melanoma.
Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
[TBL] [Abstract][Full Text] [Related]
3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
4. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
6. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
[TBL] [Abstract][Full Text] [Related]
8. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
Schlagenhauff B; Schittek B; Ellwanger U; Stroebel W; Blum A; Schwarz M; Rassner G; Garbe C
Melanoma Res; 2000 Oct; 10(5):451-9. PubMed ID: 11095406
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
[TBL] [Abstract][Full Text] [Related]
11. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.
Beyeler M; Waldispuhl S; Strobel K; Joller-Jemelka HI; Burg G; Dummer R
Dermatology; 2006; 213(3):187-91. PubMed ID: 17033166
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
13. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
14. [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
Ortiz B; Vázquez C; Martínez C; Giménez J; Sanmartín O; de los Dolores V; Ortega F; Maíquez J; Fliquete MV
Rev Esp Med Nucl; 2003; 22(2):87-96. PubMed ID: 12646097
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Jun; 31A(6):924-8. PubMed ID: 7646923
[TBL] [Abstract][Full Text] [Related]
16. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
17. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma.
Acland K; Evans AV; Abraha H; Healy CM; Roblin P; Calonje E; Orchard G; Higgins E; Sherwood R; Russell-Jones R
Br J Dermatol; 2002 May; 146(5):832-5. PubMed ID: 12000380
[TBL] [Abstract][Full Text] [Related]
18. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
Alber B; Hein R; Garbe C; Caroli U; Luppa PB
Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
20. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.
Wollina U; Karte K; Hipler UC; Knöll B; Kirsch K; Herold C
J Cancer Res Clin Oncol; 2000 Feb; 126(2):107-10. PubMed ID: 10664251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
